WeLeader Biomedical Co., Ltd. (TPEX:7713)

Market Cap	3.34B
Revenue (ttm)	1.06B
Net Income (ttm)	191.02M
Shares Out	45.48M
EPS (ttm)	4.33
PE Ratio	16.96
Forward PE	n/a
Dividend	3.37 (4.59%)
Ex-Dividend Date	Jun 3, 2025

Volume	25,009
Average Volume	14,756
Open	73.80
Previous Close	74.50
Day's Range	73.10 - 74.00
52-Week Range	54.20 - 83.00
Beta	n/a
RSI	45.72
Earnings Date	Mar 13, 2026

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Employees: 199
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7713

Financial Performance

In 2024, WeLeader Biomedical's revenue was 991.13 million, an increase of 5.36% compared to the previous year's 940.70 million. Earnings were 170.21 million, an increase of 11.77%.